The pharmacokinetics of carumonam after a single 1,000-mg intravenous infusion (20 min) were evaluated in four groups of subjects who had various degrees of renal impairment: group 1, CLCR > 60 ml/min; group 2, CLCR = 30 to 60 ml/min; group 3, CLCR = 10 to 30 ml/min; and group 4, CLCR < 10 ml/min). The elimination half-life of carumonam increased with decreasing creatinine clearance (CLCR) from 1.7 h in group 1 to 11.3 h in group 4. Peak carumonam concentration (103 ,ug/ml) and steady-state volume of distribution (12.8 liters) did not change with decreasing CLCR. Total body clearance (r = 0.98), renal clearance (r = 0.98), and nonrenal clearance (r = 0.67) of carumonam correlated with decreasing CLCR. Mean nonrenal clearance was 21 ml/min in group 1 and 12 ml/min in group 4. With regard to dosage, patients with a CLCR above 60 ml/min should receive their standard maintenance dose of carumonam without any changes; patients with a CLCR between 30 and 60 ml/min should receive the dose every 12 h; and individuals with a CLCR between 10 and 30 ml/min should be given the dose once a day. Patients with a CLCR of less than 10 ml/min should receive one-half of the dose once a day. Our recommended dosage regimens should produce within the CLCR borderlines of each group average plasma concentrations that are between one and two times that achieved in normal subjects with a t.i.d. dosage regimen.
Carumonam (Fig. 1 ) is a new synthetic N-sulfonated monocyclic beta-lactam antibiotic. This compound is highly stable against both chromosomal-and plasmid-mediated beta-lactamases and has broad-spectrum activities against gram-negative bacteria. The in vivo and in vitro activities of carumonam are comparable to those of aztreonam, a structurally related compound (9) . The pharmacokinetic characteristics of carumonam include low protein binding (Junbound = 0.82); elimination primarily by glomerular filtration (furine = 0.7 to 0.9); distribution into extracellular water space; and a half-life of elimination (t01/2) between 1. 4 
and 2.3 h (20).
These pharmacokinetic characteristics are similar to those of the cephalosporins cefsulodin, ceftizoxime, and ceftazidime (15) . As with these and other beta-lactam antibiotics with low protein binding and high urinary recovery, loss of renal function should result in an almost proportional decrease in body clearance and a corresponding increase in biological half-life for carumonam.
The purpose of this study was to define the pharmacokinetic behavior of carumonam in patients with renal insufficiency and to deduce from these data appropriate dosage schedules for such patients.
MATERIALS AND METHODS
Subjects. All healthy volunteers and renal disease patients gave informed written consent before entering the study. The study protocols were approved by the Institutional Committees of Human Investigations, Medical Outpatient Department, University of Bern (renal disease patients), and the Department of Internal Medicine, Medical Outpatient Department, Cantonal Hospital, Basel (healthy volunteers). In total, the elimination kinetics of carumonam were studied in 8 healthy volunteers (7 men and 1 woman) and 17 patients (11 men and 6 women) with different degrees of renal function. The subjects were categorized according to * Corresponding author. creatinine clearance (CLCR): group 1, subjects with normal and close-to-normal renal function (CLCR > 60 ml/min); group 2, patients with mild renal insufficiency (CLCR of 30 to 60 ml/min); group 3, patients with moderate renal insufficiency (CLCR of 10 to 30 ml/min); and group 4, patients with severe renal insufficiency (CLCR < 10 ml/min). The characteristics of the four groups are shown in Table 1 Assay procedures. A high-pressure liquid chromatographic method, described in detail elsewhere (H.-J. Egger and G. Fischer, submitted for publication), was used to determine plasma and urine levels of carumonam.
Briefly, the sample work-up involved buffering the plasma samples to pH 6.0 with potassium phosphate buffer, protein precipitation with acetonitrile, and purification of the aqueous phase containing the beta-lactam by extraction with methylene chloride. Urine was simply diluted with buffer.
The separation and quantification were achieved by using a mobile phase based on either ion suppression or ion-pair chromatography on a reversed-phase column with UV detection. For the analysis of plasma samples from patients with renal disease, a different mobile phase with precolumn backflash was applied. The limit of determination with 0.5-ml plasma specimens was 0.5 and 2 pLg/rrl for samples from healthy volunteers and patients suffering from severe renal disease, respectively; for urine samples, the limit was 25 and 20 ,ug/ml, respectively, with 50-LI specimens.
The assay was linear in the range of 0.5 to 200 ,ug/ml of plasma and 20 to 8,000 ,ug/ml of urine. The coefficient of variation (r2) was 0.9999 (0.999 for determination of plasma from patients with renal disease), using the weighting factor 1/y2. The recovery of Ro 17-2301 was quantitative. The interassay variation during this study was less than 7% (0.5 to 80 ,ug/ml) for plasma and less than 6% (25 to 4,000 p.g/ml) for urine.
Pharmacokinetic analysis. With the exception of one subject, a biexponential equation was fitted as reported previously (20) to the carumonam plasma concentration-time data (C,t), using the NONLIN (12) (4, 17) . The CLNR and volume of distribution are under these circumstances thought to be unaffected by renal disease (4, 17) . The magnitudes of the clearance and half-life changes depend only on the fraction of dose excreted in the urine of normal subjects. The larger this fraction the larger are the changes in CLT and 4/20 (4 Table 2 for CLS, /2 and Vs and the correlation found between CLT, CL T, and CLCR ( Fig. 3 and   4 ) are in agreement with these expectations.
The decrease in CLNR with declining renal function ( 5) cannot be explained solely by the lower mean, ge of the subjects in group 1 since the 4ecrease was also significant (P < 0.05) between groups 2 and 4. Other niechanisms responsible for the decline in CLNR of carumonam have not been elucidated. A similar decline in the nonrenal (mainly hepatic) cleararlce of other drugs has previously been reported in patients with renal failure (5, 7, 8, 19) . That certain! drugmetabolizing activities are decreased in, acute or chronic renal failure is well established (10, 11, 13) . For instance, the hydroxylation of acetanilide is significantly impaired in uremic rats when compared with healthy control animals (10, 11) . In four of our patients (two in group 2 and one each in groups 3 and 4), function was assessed by measuring the galactose elimination capacity (data not shown) (18) . Despite the absence of biochemical or anamnestic evidence of liver disease, all four patients exhibited a decreased galactose elimnination capacity, indicating an impaired liver function (18) .
Normally, when the relationship between CLT and CLCR is examined by linear regression (Fig. 3) , it is assumed that the ordinate intercept is an estimate of CLNR. However, since CLNR decreased with CLCR in our subjects (Fig. 5) , the ordinate intercept in Fig. 3 
